Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.91 |
| ▸ | ADRB2 | P07550 | 19/20 | 0.91 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844813 | 1.00 | CHRM3 (0.91) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2844805 | 1.00 | CHRM3 (0.91) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2846794 | 0.93 | CHRM3 (0.91) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2846804 | 0.93 | CHRM3 (0.91) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2846800 | 0.93 | CHRM3 (0.91) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2851226 | 0.92 | CHRM3 (1.00) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2851217 | 0.92 | CHRM3 (1.00) | CHRM3ADRB2CHRM2 | |
| SCHEMBL2851229 | 0.92 | CHRM3 (1.00) | CHRM3ADRB2CHRM2 | |
| SCHEMBL5652380 | 0.90 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL2847050 | 0.90 | CHRM3 (1.00) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-06 | — | — | US | claimed |
| US-7141671-B2 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE, INC. (US) | 2006-11-28 | — | — | US | claimed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | claimed |
| EP-3012254-A1 | BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS | Theravance Respiratory Company, LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2246345-B1 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE RESPIRATORY CO LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2246345-A1 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance Inc (US) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208176-A1 | Biphenyl-2-ylcarbamic acid 1-{7-[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]heptyl}piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, chronic obstructive pulmonary disease and asthma | ADRB2, ADRA2B, ADRB1 | CHRM3 24/4885ADRB2 1/4885CHRM2 12/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | CHRM3 17/4885ADRB2 2/4885CHRM2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.